ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health S...
February 12 2020 - 5:30AM
ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of its
flagship cellular health supplement Tru Niagen® (nicotinamide
riboside) as a supplement offering in Nestlé Health Science’s
(NHSc) personalized nutrition service – Persona Nutrition.
Persona is a personalized nutrition program that provides an online
health assessment, a doctor-recommended vitamin routine, and
monthly home delivery service.
There is an increasing amount of nutrition
science available supporting the importance of maintaining the
body’s NAD (nicotinamide adenine dinucleotide), a coenzyme
important for cellular health, exercise, sleeping soundly and
turning the food we eat into energy. ChromaDex’s patented Tru
Niagen® is clinically proven to increase NAD levels.
“We appreciate Persona’s focus on personalized
health and customer experience for its subscribers,” says ChromaDex
CEO Rob Fried. “Nestlé Health Science shares our
commitment to science, and we are pleased to extend our partnership
with them to include personalized nutrition.”
“Cellular health is at the core of the concept
of beauty, from the inside out. As more health-conscious consumers
want to optimize their health and wellness holistically, we are
proud to partner with ChromaDex to offer its leading NAD-boosting
Tru Niagen supplement to our customers,” says Persona CEO Jason
Brown. “Tru Niagen is supported by published clinical studies and
manufactured with the highest standard of safety and quality, which
fits in nicely with our current portfolio of top-of-the-line
nutritional supplements.”
In December 2018, ChromaDex entered into a
license and supply agreement for NIAGEN® (nicotinamide riboside)
with Nestlé Health Science, a global leader in pioneering quality
science-based nutritional health solutions. The agreement provides
NHSc the exclusive right to include CDXC’s patented nicotinamide
riboside ingredient Tru Niagen in NHSc branded medical nutrition,
and co-exclusive rights to include Tru Niagen in certain products
within the consumer health category.
Niagen® is the only commercially available NR
which has twice been successfully reviewed under U.S. Food &
Drug Association's (FDA) new dietary ingredient (NDI) notification
requirement and has also been successfully notified to the FDA as
generally recognized as safe (GRAS). ChromaDex has also secured
regulatory approvals on its patent-protected ingredient in Canada,
the European Union, and Australia.
For additional information on the science
supporting Tru Niagen, please visit www.truniagen.com.
For additional information on Persona, please
visit www.personanutrition.com.
About TRU NIAGEN®:TRU NIAGEN®
is a branded dietary supplement brought to market by key
nicotinamide riboside chloride innovator and patent holder,
ChromaDex. NIAGEN® nicotinamide riboside chloride (NR), also
supplied by ChromaDex, is the sole active ingredient in TRU
NIAGEN®. Multiple clinical trials demonstrate NIAGEN® is proven to
boost NAD (nicotinamide adenine dinucleotide) levels, which decline
with age. Only NIAGEN® has twice been successfully reviewed under
FDA's new dietary ingredient (“NDI”) notification program, and has
also been successfully notified to the FDA as generally recognized
as safe (“GRAS”). ChromaDex has also secured regulatory approvals
on its patent-protected ingredient in Canada, the European Union,
and Australia.
About ChromaDex:ChromaDex Corp.
is a science-based integrated nutraceutical company devoted to
improving the way people age. ChromaDex scientists partner with
leading universities and research institutions worldwide to uncover
the full potential of NAD and identify and develop novel,
science-based ingredients. Its flagship ingredient, NIAGEN®
nicotinamide riboside chloride, sold directly to consumers as TRU
NIAGEN®, is backed with clinical and scientific research, as well
as extensive IP protection. TRU NIAGEN® is helping the world AGE
BETTER®. ChromaDex maintains a website at www.chromadex.com to
which ChromaDex regularly posts copies of its press releases as
well as additional and financial information about the Company.
About Persona™Persona™, a
Nestlé Health Science (NHSc) company, creates science-backed,
uniquely personalized vitamin programs. Each customized program
uses high-quality, bioavailable ingredients, delivered to
customers' doorsteps. The proprietary algorithm used for the
assessments is based on scientific research reviewed by the
company’s team of MDs, RDs and nutritionists, and factors in
lifestyle, individual needs, and prescription medications to
deliver vitamin and supplement recommendations as unique as the
consumer. Persona Nutrition is available in more than 60 countries
via worldwide shipping. Persona is a supporter of Vitamin Angels®.
With every Persona vitamin pack order, at least two children who
are at risk of malnutrition receive a full year of vitamins. To
learn more, please visit www.personanutrition.com or
www.nestlehealthscience.com.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2018, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Media Contact:Alex
Worsham, Senior Director of Global Corporate
Communications310-388-6706 ext. 689alexw@chromadex.com
Persona Media Contact:Andrea
Martin, Public
Relations443-927-6183andream@personanutrition.com
ChromaDex Investor Relations
Contact:Brianna Gerber, Vice President of FP&A and
Investor Relations949-419-0288 ext. 127briannag@chromadex.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/2226e85d-2330-4bc7-98ac-934170e148d0
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024